On November 2, 2022, in West Chester, Pennsylvania, Scientist.com hosted Vendor Discovery Day. As one of the leading CROs right behind new drug R&D pipelines, Creative Biolabs participated in the event and had a pleasant time talking with researchers from Teva Pharmaceuticals.
New York, United States - November 10, 2022 /MarketersMEDIA/ —
The return of in-person networking conferences in 2022 has inspired Creative Biolabs to become actively involved in a number of industry affairs. Even though the fourth quarter of 2022 is almost halfway over, the company is still considering adding more events to its schedule for November and December. Last week, on November 2, 2022, Creative Biolabs took part in an intensive industry event, Vendor Discovery Day, held by an industry marketplace for medical research.
"This event is hosted by one of our valued partners, Scientist.com, with whom we've been collaborating for years," according to a delegate, "and we're happy to see that they're holding networking events that allow CROs like us to communicate face-to-face with researchers from renowned pharmaceutical companies. This time we met researchers from Teva and were inspired by the progress they've achieved so far."
Creative Biolabs has unique proficiencies in antibody-based therapies and has established a one-stop pipeline to handle customers' projects in a systematic manner. mAbs, sdAbs, bsAbs, and ADCs are just a few of the many antibody modalities that can be designed, engineered, and produced by Creative Biolabs using cutting-edge technology platforms.
With the Magic™ platform, scientists at Creative Biolabs can support protein products that are affordable and fit the demands of many research objectives, including immunogens and delivery vehicles.
"Another tactic we presented that day was De Novo Antibody Sequencing," added the delegate, "which is based on the proprietary Database Assisted Shotgun Sequencing (DASS) technology and can achieve 100% coverage of desired regions with excellent accuracy and precise differentiation between leucine and isoleucine."
"This intensive event between vendors and researchers provides us a great platform to show what we're really good at," said the delegate, "and our next line of action will be the exhibition at the Antibody Engineering and Therapeutics US 2022 in December, where you can learn more about our capabilities in antibodies."
Learn more about Creative Biolabs' event schedules at https://events.creative-biolabs.com/.
Profile
Creative Biolabs is a CRO devoted to novel antibody and immunotherapy discovery, providing one-stop solutions supportive of the entire pipeline. Years of experience in exploration have earned Creative Biolabs a good reputation in the industry. Bearing the aim to showcase capabilities and seek partnership opportunities, a team of scientists from Creative Biolabs embarked on the journey to global networking conferences within their scope of specialties. In December 2022, scientists from Creative Biolabs will show up at the #1 antibody engineering conference—Antibody Engineering & Therapeutics US 2022.
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://www.creative-biolabs.com/
Release ID: 89084550
If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.
